FDA Approves AVTOZMA® for Expanded Treatment of Cytokine Release Syndrome
FDA Expands Uses for AVTOZMA®
On August 6, 2025, Celltrion, Inc. announced exciting news in the realm of biopharmaceuticals. The U.S. Food and Drug Administration (FDA) has granted an expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation, now allowing its use in treating cytokine release syndrome (CRS) in both adult and pediatric patients aged 2 years and older. This marks a major advancement in therapeutic options for a condition that can swiftly become life-threatening.
What is Cytokine Release Syndrome?
Cytokine release syndrome is an often severe condition characterized by an overactive immune response resulting in a surge of cytokines into the bloodstream. This
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.